

**Vaccibody appoints Mikkel Wandahl Pedersen as new Chief Scientific Officer and Agnete B. Fredriksen as Chief Innovation & Strategy Officer**

**Oslo, Norway, May 12, 2021** – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today the appointments of Mikkel Wandahl Pedersen as new Chief Scientific Officer (CSO) and Agnete B. Fredriksen as Chief Innovation & Strategy Officer.

Mikkel Wandahl Pedersen (47) has many years of experience as a scientific leader in drug discovery with a track record of bringing drug candidates from concept to the clinical phase. Mikkel Wandahl Pedersen comes to Vaccibody from a position as CSO of Symphogen, a subsidiary of Servier, discovering and developing antibody-based drugs for the treatment of cancer as well as inflammatory and infectious diseases.

Mikkel Wandahl Pedersen, in-coming Chief Scientific Officer, says: “I am very impressed with Vaccibody’s achievements and results over the past years, both in terms of R&D collaborations, and clinical results. On this background, I am thrilled to join Vaccibody in these exciting times where vaccines during the COVID-19 pandemic have truly demonstrated their critical role in the prevention of disease. I am convinced that Vaccibody’s unique platform technology and clinical programs will make a real difference for patients in need of novel therapies.”

In her role as Chief Innovation & Strategy Officer, Agnete B. Fredriksen’s responsibilities will include both the Strategy and Business Development areas. In addition, Agnete B. Fredriksen will prioritize maintaining Vaccibody’s external scientific relations as well as the dialogue with international specialist investors and equity analysts. Agnete B. Fredriksen have already for several years spent a significant amount of her time in the above areas which have grown in both significance and volume in connection with the growth of the company.

Agnete B. Fredriksen, Chief Innovation & Strategy Officer, says: “Since co-founding Vaccibody in 2007, both the Company and I have been on an exciting, fun and extremely busy journey. With Mikkel joining Vaccibody as new CSO, I look very much forward to concentrating my energy on innovation, strategy as well as the Company’ external scientific and specialist investor relations. These are exciting areas which have grown in importance and where I believe that I can create the most value for Vaccibody in the next phase of our development. Finally, I cannot wait to work very closely with Mikkel for the period to come and ensure a successful transfer of responsibilities.”

Chief Executive Officer of Vaccibody, Michael Engsig, comments: “I am extremely pleased with the new constellation of our leadership team. This is the best of two worlds and will further energize Vaccibody in its continued growth journey. Both Mikkel and Agnete brings tremendous experience and excellence with them.”

Mikkel Wandahl Pedersen and Agnete B. Fredriksen will commence their roles at Vaccibody on June 1, 2021, and both will report to Michael Engsig, Chief Executive Officer.

### **About Vaccibody**

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody’s vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the head & neck. Further, the Company has collaborations with Roche and Nektar Therapeutics within oncology.

Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications, including its second-generation COVID-19 vaccine program, VB10.COVID2.

Vaccibody’s shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at <http://www.vaccibody.com>

### **Contact for Vaccibody:**

CEO Michael Engsig  
Vaccibody AS  
Cell: +45 6173 1509  
[mengsig@vaccibody.com](mailto:mengsig@vaccibody.com)

### **Vaccibody AS**

Oslo Science Park  
Gaustadalléen 21  
0349 Oslo, Norway

**Forward-looking statements for Vaccibody**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.